Oropharyngeal lymphomas are rare, typically high-grade neoplasms. We describe a case of plasmablastic lymphoma that originated in the oropharynx of a 40-year-old man who was positive for human immunodefi ciency virus (HIV). The diagnosis was based on fi ne-needle aspiration cytology of the mass followed by histopathologic examination supplemented with immunophenotyping. The mass was excised, but the patient refused antiretroviral therapy, and he died within 6 months of the diagnosis. In HIV-positive patients, non-Hodgkin lymphomas frequently involve sites, including the oropharynx, that are unusual in patients without HIV.
Introduction
It is well known that immune defi ciency, be it congenital or acquired, increases the development of malignancies in certain organs. In patients with acquired immune defi ciency syndrome (AIDS), non-Hodgkin lymphoma (NHL) is the second most common malignancy. 1 The prevalence of NHL in AIDS patients is approximately 100 times greater than it is in patients without AIDS. 2 In 3 to 5% of all patients who are positive for human immunodefi ciency virus (HIV), NHL is the initial manifestation of AIDS, and it serves as an AIDS-defi ning condition. 3 HIV-positive patients have a marked propensity for lymphoma in extranodal sites. Documented NHLs in AIDS patients include systemic lymphoma, primary central nervous system lymphoma, and two rare entities: primary effusion lymphoma and oral plasmablastic lymphoma. 2 Plasmablastic lymphoma almost always occurs in HIV-infected patients, and it preferentially localizes in the oral mucosa. 2 It has been estimated that plasmablastic lymphoma affects 2.6% of all cases of AIDS-NHL. 1 Clinically, this tumor exhibits a highly malignant behavior, and the prognosis is poor, even after polychemotherapy with or without radiotherapy. 3 In AIDS patients, the gingiva is the most common site of NHL of the oral cavity, accounting for more than half of all reported cases. Other head and neck sites include the palate, tongue, tonsils, nasopharynx, orbit, parotid gland, maxillary sinus, soft tissue, and hypopharynx. 4 In this article, we report a case of plasmablastic lymphoma that originated in the oropharynx, which is an unusual site for NHL in the general population.
Case report
A 40-year-old man with HIV infection presented with a painless oropharyngeal mass that impaired his ability to swallow. On examination, the mass was found to arise from the right inferior gingivobuccal sulcus (fi gure 1). A loss of teeth in the adjoining area was noted; an x-ray of the area of the lost teeth revealed no associated bone involvement.
A fi ne-needle aspiration biopsy of the mass was obtained. Histologic examination revealed that the tumor contained a proliferation of atypical lymphoid cells with plasmacytic differentiation. The plasmacytic differentiation was identifi ed by the presence of blastic-appearing cells, eccentric nuclei, an occasional perinuclear hof, dispersed chromatin, and one to several prominent nucleoli (fi gure 2, A). Histology also demonstrated necrosis and numerous mitotic fi gures, the latter indicating an extremely high proliferation index. Immunophenotypic analysis revealed tumor positivity for CD138 (syndecan-1) (fi gure 2, B) and negativity for leukocyte common antigen (LCA), CD20, human herpesvirus 8 (HHV-8), light chains, and epithelial membrane antigen (EMA). In view of these cytomorphologic and immunophenotypic features, we established a diagnosis of plasmablastic lymphoma, which is almost always associated with AIDS. The mass was excised, but the patient refused antiretroviral therapy. His condition rapidly deteriorated, and he died within 6 months of the diagnosis.
Discussion
AIDS-associated lymphomas are defi ned as those that occur with increased frequency in HIV-infected patients. 5 AIDS patients with an NHL display several features that differ from those exhibited by non-AIDS patients with an NHL. The former frequently present with aggressive extranodal disease, which portends a poor outcome. 2 From a pathologic standpoint, AIDS-associated NHLs are characterized by a diffuse growth pattern, cellular pleomorphism, high-grade morphology, and B-cell derivation. 2, 5 The prevalence of plasmablastic lymphoma in patients with AIDS-associated NHL has been estimated at 2.6%. 1 Most of the reported cases of HIV-lymphomas were of B-cell origin as opposed to plasmablastic lymphoma, as determined by CD20 positivity. 3 These tumors were designated as plasmablastic because they contained large blastic tumor cells that exhibited an immunophenotypic profi le of differentiated plasma cells with (1) absent or weak expression of B-cell markers and (2) strong reac-tivity for plasma-cell-associated antigens such as CD38 and CD138. 6 Plasmablastic lymphomas are negative for LCA, HHV-8, light chains, and EMA. 5, 6 Plasmablastic lymphoma must be differentiated from immunoblastic lymphoma, which sometimes shows plasmacytoid differentiation. The distinction can be made on immunophenotypic grounds; immunoblastic lymphoma exhibits a strong expression of CD20 and CD45. 2 The differential diagnosis includes two variants of plasma cell myeloma: the so-called plasmablastic myeloma and anaplastic plasmacytoma/myeloma. Plasmablastic myeloma should be considered when plasmablastic cells make up more than 2% of the plasma cell population. Anaplastic plasmacytoma/myeloma is more pleomorphic in appearance, with irregular nuclear and cytoplasmic contours and wide variations in cell size. Moreover, AIDS-related plasmablastic lymphoma is composed entirely of blastic-appearing cells, and it does not contain the proplasma cells and mature plasma cells that are typical of plasmacytoma. An absence of both serum monoclonal protein and extensive bone involvement that is characteristic of most cases of plasmablastic lymphoma goes against a diagnosis of plasmacytoma. Awareness of the morphologic and immunohistologic features of plasmablastic lymphoma can contribute greatly to the diagnostic differentiation between it and other malignancies with overlapping features. Plasmablastic lymphoma can also be a harbinger of an underlying immunodefi ciency.
